文献速递脊柱关节炎

司库奇尤单抗对比阿达木单抗生物类似药对放射学轴性脊柱关节炎患者放射学进展的影响:头对头随机IIIb期研究结果

Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: Results From a Head-to-Head Randomized Phase IIIb Study.
PubMed 文献 · Arthritis Rheumatol · 2024-04-30

SURPASS研究纳入859例有放射学进展高风险的放射学轴性脊柱关节炎初治生物制剂患者,随机接受司库奇尤单抗150mg、300mg或阿达木单抗生物类似药SDZ-ADL 40mg治疗。第104周时,三组无放射学进展比例分别为66.1%、66.9%和65.6%,两司库奇尤单抗剂量组与SDZ-ADL组均无显著差异,mSASSS平均变化分别为0.54、0.55和0.72。

要点

  • 第104周无放射学进展比例:司库奇尤单抗150mg组66.1%、300mg组66.9%、SDZ-ADL组65.6%,两司库奇尤单抗剂量组与SDZ-ADL组比较均无显著差异。
  • mSASSS自基线平均变化:司库奇尤单抗150mg组0.54、300mg组0.55、SDZ-ADL组0.72。
  • 基线有≥1个韧带骨赘者中第104周无新韧带骨赘比例:150mg组56.9%、300mg组53.8%、SDZ-ADL组53.3%。

核心结论

  • 两年内脊柱放射学进展程度低,司库奇尤单抗与SDZ-ADL组间无显著差异,两种治疗的安全性与此前报告一致。

研究设计与样本

  • IIIb期SURPASS研究为头对头随机研究,纳入生物制剂初治的活动性放射学轴性脊柱关节炎且放射学进展高风险(hsCRP≥5 mg/L和/或脊柱X线显示≥1个韧带骨赘)患者,按1:1:1随机接受司库奇尤单抗150mg、司库奇尤单抗300mg或SDZ-ADL 40mg治疗。

主要发现

  • 共859例患者接受治疗(司库奇尤单抗150mg组n=287、300mg组n=286、SDZ-ADL组n=286),基线男性78.5%、mSASSS 16.6、BASDAI 7.1、hsCRP 20.4 mg/L、73.0%有≥1个韧带骨赘。
  • 第104周无放射学进展(mSASSS自基线变化≤0.5)比例:司库奇尤单抗150mg组66.1%、300mg组66.9%、SDZ-ADL组65.6%,两司库奇尤单抗剂量组与SDZ-ADL组比较P=无显著差异。
  • 第104周mSASSS自基线平均变化:司库奇尤单抗150mg组0.54、300mg组0.55、SDZ-ADL组0.72。
  • 基线有≥1个韧带骨赘者中第104周无新韧带骨赘比例:司库奇尤单抗150mg组56.9%、300mg组53.8%、SDZ-ADL组53.3%。
  • 未发现非预期安全性发现。

关键数值与推荐

  • 放射学进展高风险定义为hsCRP≥5 mg/L和/或脊柱X线显示≥1个韧带骨赘。
  • 无放射学进展定义为mSASSS自基线变化≤0.5。
  • 主要终点为第104周司库奇尤单抗组对比SDZ-ADL组无放射学进展的患者比例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Spinal radiographic progression is an important outcome in radiographic axial spondyloarthritis (SpA). The objective of the phase IIIb SURPASS study was to compare spinal radiographic progression in patients with radiographic axial SpA treated with secukinumab (interleukin-17A inhibitor) versus adalimumab biosimilar (Sandoz adalimumab [SDZ-ADL]; tumor necrosis factor inhibitor). METHODS: Biologic-naive patients with active radiographic axial SpA, at high risk of radiographic progression (high-sensitivity C-reactive protein [hsCRP] ≥5 mg/L and/or ≥1 syndesmophyte[s] on spinal radiographs), were randomized (1:1:1) to secukinumab (150/300 mg) or SDZ-ADL (40 mg). The proportion of patients with no radiographic progression (change from baseline [CFB] in modified Stoke Ankylosing Spondylitis Spinal Score [mSASSS] ≤0.5) on secukinumab versus SDZ-ADL at week 104 (primary endpoint), mean CFB-mSASSS, proportion of patients with ≥1 syndesmophyte(s) at baseline with no new syndesmophyte(s), and safety were evaluated. RESULTS: Overall, 859 patients (78.5% male, mSASSS 16.6, Bath Ankylosing Spondylitis Disease Activity Index 7.1, hsCRP 20.4 mg/L, and 73.0% with ≥1 syndesmophyte[s]) received secukinumab 150 mg (n = 287), secukinumab 300 mg (n = 286), or SDZ-ADL (n = 286). At week 104, the proportion of patients with no radiographic progression was 66.1%, 66.9%, and 65.6% (P = not significant, both secukinumab doses) and mean CFB-mSASSS was 0.54, 0.55, and 0.72 in secukinumab 150 mg, secukinumab 300 mg, and SDZ-ADL arms, respectively. Overall, 56.9%, 53.8%, and 53.3% of patients on secukinumab 150 mg, secukinumab 300 mg, and SDZ-ADL, respectively, with ≥1 syndesmophyte(s) at baseline did not develop new syndesmophyte(s) by week 104. There were no unexpected safety findings. CONCLUSION: Spinal radiographic progression over two years was low with no significant difference between secukinumab and SDZ-ADL arms. The safety of both treatments was consistent with previous reports.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Baraliakos X, Østergaard M, Poddubnyy D, et al. Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: Results From a Head-to-Head Randomized Phase IIIb Study. Arthritis Rheumatol. 2024. PMID: 38556921. doi:10.1002/art.42852

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。